In a large phase 2 study [92], involving 168 ALK-rearranged NSCLC patients who progressed on crizotinib and were treated with ensartinib, ct-DNA was analyzed at baseline and a progression disease with a 212-gene panel. This evidence concerns the gene ALK and non-small cell lung carcinoma.